Radiesse came to market through the FDA's premarket approval route. That route required clinical evidence for a named cosmetic use in a named area. It makes the approved list unusually specific:
Moderate to severe facial wrinkles and folds, "such as nasolabial folds", and facial fat loss (lipoatrophy) in people with HIV: Both were approved 22 December 2006.
Hand augmentation to correct volume loss in the dorsum of the hands: Approved 4 June 2015.
Moderate to severe loss of jawline contour in adults over 21, for Radiesse (+) Lidocaine. Approved 1 September 2021.
Correction of decollete wrinkles in patients 22 and older, at a 1:2 dilution with saline. Approved 31 March 2026.
The temple is not on that list, and no Radiesse supplement names it.
Radiesse is calcium hydroxylapatite microspheres in a gel carrier. The gel gives immediate volume. The microspheres left behind prompt the body to build collagen around them over the following months.
This is the correction worth making. A lot of writing on this topic says no filler is approved for the temples. That has not been true since 2023.
Juvéderm Voluma XC, approved for the temple on 6 October 2023: The indication reads, in part, "for supraperiosteal injection to augment the temple region to improve moderate to severe temple hollowing in adults over the age of 21." Its trial randomised 171 people 2:1 against a no-treatment control, with blinded evaluators. It reported 80.4% responders at month 3 versus 13.5%, and 73.3% still responding at 13 months. Unusually, the FDA also required a device-specific injector training programme for this indication. That programme was approved separately in 2024 and updated in 2025. It is a real restriction. The temple indication is not open to any injector who has not completed the training.
Restylane Contour, approved for the temple on 20 March 2026: "Restylane Contour is indicated for correction of temple hollowing in patients over the age of 21." Its trial enrolled 225 people against a no-treatment control, with blinded evaluators. It reported 91.2% responders at month 3 versus 9.1%. Follow-up was scheduled to 18 months.
Do not read those two responder rates as a ranking: They come from separate trials, using different manufacturer-developed scales, in different populations. Nothing in either trial compares one product with the other. A number from one cannot be set against a number from the other.
Both are hyaluronic acid fillers. That matters in this area specifically, because hyaluronic acid can be broken down with hyaluronidase and Radiesse cannot.
Two separate problems, and they are worth separating.
Blood vessels: The temple carries the superficial temporal artery, the middle temporal vein and the deep temporal arteries, and its vessels connect toward the orbit. That connection is the route by which filler injected under pressure can travel backwards along an artery and then forwards into the vessels supplying the retina. The volume needed is very small: in one review, the amount required to fill the supratrochlear artery from the glabella to its bifurcation averaged 0.085 mL — less than a tenth of a standard syringe.
The gliding plane: The temple contains a broad plane where tissue slides, and product placed there can travel away from where it was put. A 2026 case report describes a woman with persistent swelling of both upper eyelids whose MRI and thyroid workup were unremarkable; surgery eventually found deposits consistent with hyaluronic acid in the eyelid skin, and she then recalled temple filler two years earlier. The authors attributed it to migration through the avascular gliding planes of the temple.
There is one more signal worth reporting, with a caution attached. A systematic review of complications from facial fat grafting collected 58 complications in 38 published patients; most followed injection to the forehead or the temporal region, and 53% of all severe complications occurred in the temporal region. Two caveats have to travel with that figure: it is a count of published case reports with no denominator, so it says what goes wrong and where but not how often, and it is about autologous fat, not about Radiesse. It is evidence that the region is unforgiving, not evidence about this product.
A 2025 systematic review of non-surgical temple volumisation is the best available summary: It covered 40 articles and 881 patients. The materials used break down as hyaluronic acid 783 patients, calcium hydroxylapatite 93, PMMA 28, allograft adipose matrix 10 and poly-L-lactic acid 2. The most common reported side effects were pain, tenderness or pressure in 29.6%, ecchymosis - bruising - in 17.3%, and oedema, or swelling, in 15.5%.
Two things follow from those numbers. First, the temple literature is overwhelmingly a hyaluronic acid literature; calcium hydroxylapatite is a small minority of it. Second, the review's first author discloses consultancy or research relationships with AbbVie, Galderma and Merz — the manufacturers of the products it reviews. That does not invalidate the count, but it belongs beside it.
No randomised trial of Radiesse specifically in the temple appears in the published record: The continuing-education literature on hyperdiluting Radiesse does describe using it undiluted for deep structural support in areas including the temple — but that is case-series-level material from a Merz-linked faculty group, describing a convention rather than a tested protocol.
Off-label use is legal and routine: Doctors across medicine use approved products outside their approved indications every day, and injecting Radiesse in the temple is a normal, non-scandalous example of that. Nobody is breaking a rule.
What it changes is the evidence you are relying on. For the hands, jawline, décolleté and nasolabial folds, a regulator reviewed a clinical trial of this product in that area. For the temple, there is no such review for Radiesse — the case for it rests on anatomy, technique and case series.
And the reversibility point lands harder here than almost anywhere else on the face. If a hyaluronic acid product in the temple migrates, forms a lump or blocks a vessel, hyaluronidase is an option. With Radiesse it is not, and there is no approved reversal agent for calcium hydroxylapatite.
Questions worth asking at a consultation:
Which product are you proposing for my temples, and is the temple an approved indication for it?
If it is not, what has been published for this product in this area?
Needle or cannula, and at what depth and plane?
If something goes wrong, what can be done — and can this specific product be dissolved?
What is your plan and equipment for a suspected vascular occlusion, and where is the nearest ophthalmology cover?
Go to an emergency department or call 911 if, during or after any filler injection, you have:
Sudden vision change, double vision or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin that turns white (blanching) and then dusky, mottled or net-like
Weakness, drooping, slurred speech or any other stroke-like symptom
These can be signs that filler has entered an artery. Time matters in hours. Published guidance treats suspected retinal artery occlusion as a same-hour emergency and suspected skin occlusion as a same-day emergency, though that window comes from a 1980 primate experiment and from expert consensus, not from trials in filler patients.
Do not wait to see whether it settles, and do not use pain as your gate. In a survey of 52 experienced injectors worldwide, pain was mild or absent in 47% of the intravascular injections they reported.
Radiesse raises the stakes here: Hyaluronic acid fillers can be broken down with hyaluronidase in an emergency. Calcium hydroxylapatite cannot, and there is no approved reversal agent for it, so the response is supportive care rather than dissolving the product.
Swelling keeps growing after the first few days instead of settling
A lump appears and does not settle
Redness spreads outward from the injection site
Tenderness, redness or a firm lump turns up weeks or months later — a delayed inflammatory reaction or an infection is possible
The product looks as though it has moved from where it was placed
None of these is an emergency in the same sense as the list above, but all of them are reasons to be seen rather than to wait it out.